Drug Approval | May 05, 2026
Lupin receives USFDA approval for generic Ravicti oral liquid
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The company says the product will now be distributed exclusively through Anovo Specialty Pharmacy
New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The transaction marks a clear portfolio reshuffle for Indoco
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
Subscribe To Our Newsletter & Stay Updated
